Abstract. High vascularity correlates with poor clinical outcome in cancer of the uterine cervix. We investigated whether human cervical cancer cell (HeLa) metabolites influenced endothelial cell proliferation through the serine protease, tissue kallikrein.
Introduction
Cancer of the uterine cervix is the second most common malignancy in women and remains a leading cause of cancerrelated deaths for women in developing countries (1) . Poor clinical outcome has been found to correlate with increased tumour size, stage and vascularity (2) (3) (4) . The importance of the latter is linked to the therapeutic potential of radiotherapy in cervical cancer (5) and is supported by a consensus statement which proposed the intra-tumour microvessel density ('hot spot') technique as the method of choice for measuring angiogenesis (6) .
Angiogenesis is the recruitment of new blood vessels from the pre-existing microvasculature that occurs in normal tissue and tumours (7) (8) (9) (10) (11) . Thus, many primary tumours are able to establish continuity with the circulation to obtain nutrients and also to systemically shed metastatic cells which then target secondary sites in distant organs (12) . Tumour angiogenesis is a tightly-regulated cascade mediated by angiogenic cues emanating from stromal elements in the host organ environment (13) . Some pro-angiogenic factors shown to be involved in cervical cancer include vascular endothelial growth factor (VEGF) (14) (15) (16) and platelet-derived growth factor (PDGF) (17) . However, there are no studies on the role of tissue kallikrein (TK) in cervical cancer angiogenesis even though TK and its gene, KLK1 (EC 3.4.21.35) have been shown to induce angiogenesis in an ischaemic hind-limb model (18) and to be present in the endothelial cells of human umbilical cord vein (HUVEC) (19) and human coronary artery (20) .
TK is a serine protease whose primary function is to cleave kininogen in order to release bradykinin (BK). Other functions of TK include the proteolytic breakdown of progelatinase and pro-collagenase (21) with concomitant destabilisation of the stroma, thereby promoting the migration of both endothelial and tumour cells (22) . Although TK and KLK1 have been demonstrated in endothelial cells (19, 20) and in tumours of the human stomach (23) , oesophagus (24) and breast (25) , there are no studies on the role of the kallikrein-kinin system (KKS) in the pathogenesis of cervical cancer. Components of the KKS are also considered to form the first line onset of inflammation (26) , a process described as important in the pathogenesis of cervical cancer (27, 28) , and the vascularity observed in cervical cancer (29) . The involvement of TK in most biological processes considered to be crucial in cervical cancer, namely, tumourigenesis, angiogenesis and inflammation, makes TK an ideal candidate for further study into the pathogenesis of cervical cancer.
Previous angiogenesis models have studied neo-vascularisation without simultaneously examining any concomitant were plated onto 8-well chamber slides (Iwaki, Tokyo, Japan). At approximately 60% confluency, conditioned medium was extracted from each line and used to dose the other cell line at concentrations of 10, 25 and 50%, now designated 'challenge medium'. Thus, metabolites were presented to proliferating cell lines in a dose-controlled manner. After 24 h, the spent challenge medium was removed for TK measurement by ELISA while the cells on the chamber slides were serum-cleared and fixed in acetone/methanol (1:9, v/v). Chamber slides were stored at 4˚C, under RNasefree conditions, until TK immunochemistry and TK mRNA assays could be performed.
TK immunochemistry. The TK primary antibody, an antihuman polyclonal goat IgG raised against a recombinant human TK, was isolated and fully characterised for specificity and sensitivity, as described previously (31) . The conventional linked streptavidin-biotin (LSAB) immunolabelling method for challenged cells was performed as described previously (19). The antibody method control was normal human submandibular gland, a known source of TK (32) , and was used to demonstrate TK as described previously (33) . To distinguish between the two cell types, von Willebrand's Factor (vWF; Sigma, St. Louis, MO, USA) and cytokeratin (CK-19; Dako, Cambridgeshire, UK) was used to immunostain endothelial cells and HeLa cells, respectively. Approval for the collection and histological processing of normal submandibular gland tissues from post-mortem had been granted previously by the University of KwaZulu-Natal Biomedical Ethics Committee.
Immunostained slides were viewed, using a bright field/ phase contrast microscope (DMLB; Leica, Heidelberg, Germany) coupled to a digital camera (DFC 300FX, Leica). The C-mount adaptor between microscope and camera had a x10 magnification. Fluotar objective lenses (Leica) were used (x20, x40 and x100 magnification with numerical apertures of 0.50, 0.70 and 1.3, respectively). 3 cells/well, respectively, were grown to 60% semiconfluency. Following the challenge model where both endothelial cells and HeLa cells were each fed 10, 25 and 50% concentrations of challenge medium from the other cell line for 24 h, proliferation of both cell types were measured as follows: 10 μl of 5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide salt; Sigma] was mixed with 100 μl of pre-warmed (37˚C) cell-specific medium and then added to the cells at 37˚C/5% CO 2 for 4 h. The MTT solution was replaced with 100 μl dimethylsulfoxide (DMSO, Sigma) and the plate incubated for a further 1 h at 37˚C/5% CO 2 . Thereafter, the absorbance at 595 nm (A 595 nm ) of each well was read at on a microplate reader (Model 3550; Bio-Rad, CA, USA), and this value was normalised using the A 595 nm of non-challenged cells as a baseline 100% cell proliferation.
In situ RT-PCR (IS RT-PCR)
for TK mRNA. The method used was described previously (19). Challenged HUVEC and HeLa cells were tested for TK mRNA with the following synthetic oligonucleotide primers: KLK1-160F, 5'-CTGTACCATTTC AGCACTTTC; KLK1-742R, 5'-GCCACAAGGGACGTAGC; KLK1-790R, 5'-TCACATAAGACAGCACTCTGA (MWGBiotech AG, Ebersberg, Germany). Following thermal cycling, optimised previously (19), DIG-labelled mRNA were immuno-detected with nitro-blue tetrazolium/bromochloro-indoyl phosphate. Immunostained slides were viewed and images captured using the Leica microscope-camera system described above.
Results
Phenotypic growth profiles in the challenge model. Growth profiles of the challenged HUVECs were described previously (19). Briefly, HUVECs established an approximately 60% monolayer confluency 4 days post-seeding on 2D growth surfaces. Uniform plating distribution ensured sufficient growth and cell spreading to facilitate challenging these cells with HeLa conditioned-medium. Upon challenge with HeLa metabolites, HUVECs, in general, demonstrated no marked phenotypic change although there were some examples of spontaneous cord-like structure (CLS) formation. In contrast, HeLa cultures exhibited typical pleiomorphic, monolayer topology in the log-phase of growth, and subsequent cell clusters exhibited peripheral expansion and bridging between smaller cell conglomerates. Upon challenge with HUVEC metabolites, HeLa cell morphology did not appear to change.
Careful preparation of cell cultures minimised cell stress and consequent necrosis.
Immunostaining controls. In the submandibular gland control tissue, positive TK immunostaining was demonstrated within the ductal epithelial cells (31,32,35), but was absent within the acinus (Fig. 1A) . HUVEC and HeLa phenotypes were ONCOLOGY REPORTS 22: 285-293, 2009 287 Figure 1 . TK immunodetection in the HUVEC/HeLa challenge model: normal human salivary gland (SG) served as a method control (A) where TK label is depicted as a brown precipitate (diaminobenzidine, DAB) in salivary gland duct cells (blue arrows) but not within acinar cells (x200). The HUVEC phenotype (B) was validated by von Willebrand Factor staining in peri-nuclear (blue arrow) and interend othelial projections (black arrows) of unchallenged HUVECs (x400). Unchallenged HeLa cells (C) demonstrated peri-nuclear (blue arrows) and cell-extension (black arrows) cytokeratin (CK-19; x400). HeLa (D, x200) and HUVEC (E, x400) were negative method controls. Unchallenged HUVECs (F, x400), 10% challenged HUVECs (G, x400), 25% challenged (H, x1000) and 50% challenged (I, x400) showed TK cytoplasmic (blue arrow) and cell extension (black arrows) staining. Unchallenged HeLa (J, x400), 10% challenged (K, x400), 25% challenged (L, x400) and 50% challenged (M, x400) demonstrated diffuse cytoplasmic (blue arrows) and cell-cell extension (black arrows), with some mitotic figures (red arrows) evident in (K) and (L). Note that scale bars on (A)-(C) and (H)-(M) = 300 μm whilst the rest = 100 μm.
confirmed with the cell-specific markers vWF and CK-19, respectively, and the non-challenged HUVECs and HeLa served as cell culture controls. In the endothelial cells, vWF staining was observed in membrane extensions and peri-nuclear regions as well as in intercellular junctions in spontaneous CLS (Fig. 1B) . In HeLa monolayers, CK-19 staining was observed in the peri-nuclear cytoplasm as well in membrane extensions (Fig. 1C) . Omission of the primary antibody (TK, vWF or CK-19) and replacement with dilution buffer in the method controls demonstrated no non-specific label in both HeLa and HUVEC monolayers ( Fig. 1D and E, respectively) . In order to validate endothelial cell function in the challenge model, 50% challenged HUVECs retained vWF expression (data not shown).
TK in non-challenged HUVECs. Immunolabelling was observed in non-challenged control HUVECs (n=6; Fig. 1F ) in 50-70% of cells in each field of view. In areas of confluency, there was low intensity, evenly-distributed cellular staining.
In other regions, HUVECs demonstrated strong cytoplasmic and cell membrane labelling accompanied by intense staining in cell-cell extensions and contacts. Further, non-challenged HUVECs, embedded within confluent colonies, appeared to have little or no stain at all. Since microscopic assessment is always subject to observer bias, cellular immunostaining intensity in the HUVEC/HeLa challenge models was further quantified by image analysis (discussed later).
TK in challenged HUVECs. As the concentration of tumour challenge medium [Tu] increased, the amount of TK immunolabel in HUVECs appeared to visually decrease ( Fig. 1G-I) . Indeed, the TK label became more defined even though there appeared to be a reduction in the distribution and the intensity of staining (data not shown). Further, challenged HUVECs demonstrated some CLS formation and staining in larger cells appeared to localise on the opposite side of the cytoplasm to that of actual contact with neighbours. The visual staining intensities of cell contacts and cell extensions appeared to be similar (intense) in all challenged sets of HUVECs. (Fig. 1J) . There was extensive staining in semiconfluent regions with individual cells exhibiting intense label on mitotic figures and cell-cell contacts. As endothelial challenge medium [En] increased, the challenged HeLa cells demonstrated little/no label in confluent regions, extensive and moderate label in semi-confluent regions with intense, whole-cell TK label on most of the other cells including mitotic figures (Fig. 1K-M) Fig. 2Ai ). Small confidence interval ranges boosted the robustness of significance. In summary, the overall trend appeared to be a significant decrease in the intensity of TK labelling on HUVECs as [Tu] increased.
TK in non-
Similar analysis of [En]-challenged HeLa cells demonstrated no significant differences in TK intensity amongst any of the four groups (Fig. 2Aii) 
ELISA.
To control for inter-and intra-assay variations as well as validate ELISA results of the samples, pooled urine standards were used. Further, in order to exclude the growth: time ratio as a possible factor influencing the release of TK into the conditioned-medium, sample aliquots of conditionedmedium from HUVECs and HeLa, grown to almost complete confluency, revealed no significant increase in TK content from day 0 (day of plating) until confluency, indicating that time did not mitigate TK output (data not shown). Six independent TK ELISAs (n=6) were performed on challenge medium, with each sample measured in triplicate. The TK content in each challenge group was translated into box-plot histograms. Kruskal-Wallis and Dunn's Multiple Comparison Post Hoc Test was used to determine overall significance and intergroup significance, respectively (P≤0.05). The medium of non-challenged HUVECs contained a mean TK concentration of 18.72 ng/ml (Fig. 2Bi) . However, when these cells were challenged with [Tu] , TK significantly increased to 21.65 ng/ml (25%, P≤0.04), and peaked at 20.81 ng/ml (50%, P≤0.02), suggesting that HeLa metabolites increasingly induced HUVECs to release TK into their surrounding microenvironment in a dose-dependent manner. Fig. 2Bii demonstrates TK released into the growth medium by challenged HeLa cells, where no statistical differences could be demonstrated between the non-challenged and challenged groups. Thus, neither the presence nor the concentration of HUVEC metabolites appeared to have any effect on the amount of TK released from HeLa cells.
Cell proliferation.
To control for the proliferative effects that HUVEC metabolites would have on the growth potential of HUVECs themselves, these cells were challenged with [En] and the cell proliferation measured (data not shown). In the HUVEC-HeLa challenge model, 6 independent MTT assays (n=6) were performed where the quantitation of challenged HUVECs demonstrated a significant increase in cell proliferation (Fig. 2Ci) . For each of the [Tu] concentrations used (10, 25 and 50%), there was a statistically significant increase (192.55, 201.59 and 211.42%, respectively) compared with the non-challenged HUVEC treatment group. A similar but non-significant trend was observed in HeLa cells, with an increase in cell number in each of the 10, 25 and 50% challenged groups (106.01, 116.71 and 106.72%, respectively) compared with non-challenged HeLa cells (Fig. 2Cii) . The Student's t-test (36) was used to assess the statistical significance (P≤0.05) between groups.
IS RT-PCR controls.
The human submandibular gland positive method control demonstrated TK mRNA in the salivary gland duct cells (Fig. 3A) . and both cell types demonstrated TK mRNA label within their cytoplasm ( Fig. 3C and G) . Omission of the primers during both the reverse transcriptase and PCR reactions confirmed the specificity of this labelling. The negative control on the salivary gland showed an absence of TK mRNA label in the cytoplasm of the duct cells but some non-specific nuclear labelling (Fig. 3B) . This artefact, seen in both positive and negative tissue controls (as well as in all cultured cells), was due to non-specific nuclear labelling that occured during the PCR reaction where Taq DNA polymerase screens nuclear DNA for nicks caused by DNase, and then repairs these fragments. Consequently, DIG-dUTP from the nucleotide pool is incorporated into the repaired nuclear strands and this manifests as nuclear labelling. Negative method controls for NAIDOO and RAIDOO: ENDOTHELIAL KALLIKREIN REGULATES CERVICAL CANCER 290 Figure 3 . TK mRNA in the HUVEC/HeLa challenge model by in situ RT-PCR. TK mRNA label was visualised as an intense blue-black colour precipitated by the chromogen, nitro-blue tetrazolium/bromo-chloro-indoyl phosphate. Normal human salivary gland control tissue (A) demonstrated TK mRNA (broken arrows) in the cytoplasm of ductal cells but not in the acinar cells (x200) or in the salivary gland negative control (B, x200), Unchallenged (C, x400), 10% challenged (D, x400) and 50% challenged (E, x400) HUVECs demonstrate extensive peri-nuclear TK expression (black arrows). Cellular extensions also show TK mRNA (broken arrows) in (C), (D), (E) and (E) inset, while HUVEC method control (F) demonstrates no immunostaining (x400). Unchallenged (G, x400), 10%-challenged (H, x400) and 50%-challenged (I, x400) HeLa cells displayed extensive cytoplasmic (black arrows) and cell extension (broken arrows), while HeLa negative control (J, x400) demonstrates no cellular mRNA but does indicate mitosis (broken arrow) as well as apoptosis (double-head arrow). Note, scale bars on (B) and (F)-(J) = 300 μm, (D) and (E) = 100 μm.
HUVECs and HeLa also demonstrated no cytoplasmic mRNA labelling, although non-specific nuclear staining was evident ( Fig. 3F and J, respectively) .
TK mRNA in HUVECs. Both non-challenged and challenged HUVECs displayed TK mRNA in their cytoplasm as well as non-specific nuclear staining (Fig. 3C-E) . Specific label was generally localised to peri-nuclear regions in confluent and semi-confluent cells. Those cells that remained isolated in culture and those that exhibited cell-cell contacts demonstrated distinct mRNA within cellular extensions (Fig. 3E, inset) . In many instances, these extensions stained more intensely than those of their semi-confluent/confluent neighbours. No visual intensity differences could be discerned between challenged and non-challenged HUVECs, or amongst the various challenged HUVEC groups. These observations also included the few spontaneous CLS formations. An average of 60-80% of cells labelled for TK mRNA in all groups (mean in 5 fields of view, n=6).
TK mRNA in HeLa. Intense TK mRNA was visualised on both non-challenged (Fig. 3G ) and challenged HeLa (10% and 50%: Fig. 3H and I, respectively) in most cells demonstrating complete cytoplasmic labelling for TK mRNA. This labelling was especially prominent in cells within confluent regions, cell extensions, cell-cell contacts and actively dividing cells. In areas of cell aggregation, complete cellular staining occurred. There were no visual differences in TK mRNA staining patterns between non-challenged and challenged HeLa, or amongst the various challenged HeLa groups.
Discussion
Although the in vivo milieu is the ideal environment for studying tumour-angiogenesis, in vitro systems are also useful since they relate well to combination models of cancer and endothelial cells. Conditioned-medium models, however, afford countless biochemical variations and, by limiting functional parameters, the influence(s) of biochemical elements can be defined. Thus, the present model i) allowed angiogenic tendencies of HUVECs to be investigated whilst under the tempero-spatial influence of metabolites from cervical cancer cells, and ii) afforded bi-directional analysis of the influence of tumour and endothelial factors on cell proliferation and TK processing.
The 15 tandemly-located human TK genes on the long arm of chromosome 19 are expressed in a wide array of tissues, mainly those that are under steroid hormone control (37) . The localisation of both TK and TK mRNA in HeLa cells support the expression of TK in human cervical carcinoma. Although previous studies, including our own, have demonstrated TK expression in various human tumours and cultured human tumour cells (19, 23, 24, (38) (39) (40) (41) , this is the first study demonstrating TK in human cervical cancer HeLa cells. A previous study demonstrated the presence of human kallikrein 7 (hK7) in 80% of human cervical adenocarcinoma samples examined versus 46% of normal cervical tissue (37) , suggesting that increased hK7 expression might play a role in the pathogenesis of cervical adenocarcinoma. A recent study indicated that relatively high levels of many human tissue kallikrein-related peptidases (KLK) are present in human cervico-vaginal fluid where they may activate anti-microbial proteins as they do in perspiration (42) . An important extension of our study will be to examine the differential expression of TK in normal cervical tissue and various stages of cervical cancer since such a study will contribute to our understanding of the changing functional roles of TK during progression, invasion and metastasis in cervical cancer.
The involvement of the KKS in angiogenesis has been demonstrated by the expression of TK in bovine angiogenic endothelial cells (19, 20) , non-angiogenic HUVECs and human coronary artery endothelial cells (20) . In this study, we also demonstrate the presence of TK and TK mRNA in angiogenic HUVECs, but this is the first demonstration of the ability of metabolites from cervical cancer cells to induce the release of TK from HUVECs. In addition, we found that challenging endothelial cells with metabolites from human cervical cancer cells significantly increase the proliferation of HUVECs to form CLS while simultaneously reducing the amount of immunoreactive cellular TK, in a dose-dependent manner. The reduction in cellular TK was associated with a concomitant increase in TK within the media, supporting a proteolytic action of TK on the ECM. This novel finding that alludes to the dynamic manipulation that tumours may simultaneously exert over both TK expression and angiogenesis is supported by previous reports of TK being a stromal protease and mitogen (43) . It is also possible that these cancer metabolites modify downstream protein sequestration signals. Another explanation, as suggested by our previous study (19) , is that the apparent up-regulated TK metabolic activity is a function of its preactivation and half-life (t 1/2 ). Cellular TK, stored as inactive prekallikrein, is usually activated to TK which has proteolytic functions both within the endothelial cell and in the extracellular environment, until it is sequestered by inhibitors such as kallikrein binding protein (KBP), Protein C and kallistatin, resulting in a t 1/2 of several hours (44) (45) (46) . Our anti-TK IgG detected both the prekallikrein stored within unchallenged HUVECs as well as TK released from HUVECs following activation by cervical cancer cell metabolites. Although other studies, using PCR, amidolytic activity and receptor antagonists have demonstrated the release of active TK by human vascular endothelial cells (20) , none have demonstrated a dosedependent release due to tumour metabolites. Here, we have been able to show, by ELISA, a significant increase in total kallikrein content in the spent medium of challenged HUVECs. This increase appeared to be in direct response to tumour metabolite concentration in the conditioned-medium, and suggests functional activation of pre-kallikrein. This latter effect is supported by the studies of Shih and co-workers who showed that ovarian cancers secrete kallikreins 6, 7, 8 and 10 (47) and the Yayama group who have shown that activated TK is continually secreted by HUVECS (20) . Further, in the present study, HeLa metabolites caused significant increases in HUVEC proliferation, by as much as 200%. It is possible that HeLa, originating from a highly vascular and aggressive cervical tumour, requires a strong angiogenic profile that is achieved by the ability of HeLa metabolites to simultaneously influence pro-angiogenic factors such as VEGF and TK (and others), and endothelial cell proliferation. In our model, it is possible that TK, released in response to ONCOLOGY REPORTS 22: 285-293, 2009 tumour metabolite signals, has proteolytic and pro-invasive functions that are required at the leading edges of neovasculature development. Other pro-angiogenic factors have also demonstrated variable functions, e.g. VEGF 121 , VEGF 165 and VEGF 189 display differing biological activities due to specific microenvironments at different anatomical sites (48) .
Previous studies in animal models have reported that inflammatory stimuli promote the release of cell-bound TK with no decrease in TK mRNA levels (49) . In humans with ulcerative colitis and Crohn's disease, Stadnicki and coworkers showed that TK secretion resulted in a significant decrease in TK levels within the inflamed intestinal tissue and postulated an in vivo pro-inflammatory role for the released TK (50) . In previous studies, we also demonstrated an upregulation of gastric TK secretions in patients with gastritis (34, 51) . Immunohistochemical examination of cervical cancer tissue also demonstrates extensive infiltration of inflammatory cells such as macrophages (29) and overexpression of the pro-inflammtory marker cyclooxygenase-2 (COX-2) (28). The pro-inflammatory functions of kinins may also account for the inflammation observed in cervical cancer. Kinin receptor antagonists may be a therapeutic approach as studies on celecoxib, a COX-2 inhibitor, have shown (27) .
The discovery of the entire kallikrein genome has propagated numerous studies that implicate regulatory/dysregulatory TK expression and functional mechanisms in cancer and the associated processes of angiogenesis and metastasis. The concept of TK functional differences is also demonstrated in our tumour-angiogenesis model by the finding that HUVEC metabolites did not alter TK in either HeLa cells or its media. We have also ascertained in other experiments that neither HeLa nor neuroblastoma cells altered their TK secretion in response to the metabolites of each other (unpublished data). These results suggest that TK function and site of biological activity in cancer cells may be different from endothelial cells. However, there may be other factors (possibly endothelial or ECM-derived) that act in concert with tumour metabolites to enhance this response and mediate TK secretion exclusively in endothelial cells. Our model suggests that cancer cells are eliciting pro-angiogenic activity in HUVECs to proliferate, differentiate and migrate into the microenvironment under the influence of TK.
In conclusion, it is likely that tumour-induced, vascularderived TK that surrounds angiogenic endothelial cells: i) aids in stromal remodelling to allow angiogenesis and the release of contributing co-factors, ii) contributes to neo-vasculature invasiveness, and iii) produces a tempero-spatial chemotactic message that may be recognised by cell signalling systems. Various reports have hinted at the clinical value of tissue kallikreins as diagnostic and prognostic tools as well as future KKS agonist and/or antagonist drugs as feasible anti-cancer options. We intend to test this hypothesis by using inhibitors such as kallistatin or anti-TK antibodies in the challenge medium, and then determine changes in cell growth and invasion in the tumour angiogenic model.
